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Abstract
Background: A wealth of information on clinical trials has been provided by publicly accessible
online registries. Information technology and data exchange standards enable rapid extraction,
summarization, and visualization of information and derived knowledge from these data sets.
Clinical trials data was extracted in the XML format from the National Library of Medicine
ClinicalTrials.gov site. This data includes categories such as 'Summary of Purpose', 'Trial Sponsor',
'Phase of the Trial', 'Recruiting Status', and 'Location'. We focused on 645 clinical trials related to
cancer vaccines. Additional facts on cancer types, including incidence and survival rates, were
retrieved from the National Cancer Institute Surveillance data.
Results: This application enables rapid extraction of information about institutions, diseases,
clinical approaches, clinical trials dates, predominant cancer types in the trials, clinical opportunities
and pharmaceutical market coverage. Presentation of results is facilitated by visualization tools that
summarize the landscape of ongoing and completed cancer vaccine trials. Our summaries show the
number of clinical vaccine trials per cancer type, over time, by phase, by lead sponsors, as well as
trial activity relative to cancer type and survival data. We also have identified cancers that are
neglected in the cancer vaccine field: bladder, liver, pancreatic, stomach, esophageal, and all of the
low-incidence cancers.
Conclusion: We have developed a data mining approach that enables rapid extraction of complex
data from the major clinical trial repository. Summarization and visualization of these data
represents a cost-effective means of making informed decisions about future cancer vaccine clinical
trials.
Background
The World Health Organization's Global Burden of Dis-
ease statistics identified cancer as the second largest global
cause of death, after cardiovascular disease [1]. Cancer is
the fastest growing segment of the disease burden; global
cancer deaths are projected to increase from 7.1 million in
2002 to 11.5 million in 2030 [2]. Advances in prevention,
diagnostics and treatment of cancer have contributed to
the improved prognosis for cancer patients: one third of
cancers are preventable and another third are curable
through early detection and effective therapy [3]. New
cancer therapies are subject of vigorous research including
the application of new high-throughput biomedical tech-
nologies that generate large amounts of data. The related
information explosion mandates the use of biomedical
bioinformatics.
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Researchers and clinicians need rapid access to multiple
types of information, including molecular, clinical, and
literature databases, and clinical trials registries, as well as
suitable data analysis tools. The National Center for Bio-
technology Information (NCBI) hosts resources for
retrieval and analysis of bio-molecular data. These are
accessible through the NCBI's web site [4]. Clinical trials
data are available through clinical trials registries. Since
1971, regulatory efforts on clinical trials registration have
resulted in a significant level of compliance by both spon-
sors and conductors of clinical trials [5]. ClinicalTrials.gov
[6] has emerged as the largest registry in the world [7].
Currently it contains information on 50,000 clinical trials
including 16,000 cancer-related entries. The US National
Cancer Institute (NCI) provides access to a clinical trials
registry within the Physician Data Query (PDQ) database
[8]. The PDQ contains (Dec 2007) 21,000 abstracts of
cancer-related clinical trials and regularly exchanges data
with the ClinicalTrials.gov registry. Data sharing and
direct access to resources (researchers, computers, soft-
ware, data, research participants, and other) are consid-
ered critical for the advancement of cancer research and
the improvement of health care. The initiatives such as
Cancer Research Network [9] and Cancer Biomedical
Informatics Grid [10] provide the framework for integra-
tion of various data types and tools for cancer research.
Standardized data formats (e.g. demographics, health
plan eligibility, tumor registry, inpatient and ambulatory
utilization, medication dispensing, laboratory tests, imag-
ing procedures, others) [9] facilitate access to and sharing
of data and automated analysis.
Knowledge discovery from databases, also known as data
mining, is an emerging field that applies techniques from
databases, statistics and artificial intelligence to extract
high-level information (knowledge) from a large volume
of low-level data. Examples of high-level information
derived from low-level data include forms that are more
compact (e.g., short reports), more abstract (e.g., descrip-
tive models of the process that generated data), or more
useful (e.g., predictive models for estimating values of the
future cases) than existing low-level data [11]. Mining
clinical trials data usually refers to using statistical and
modeling tools for analysis and design of clinical trials. If
appropriate clinical trials data (e.g. aims, goals, regimens
and conditions, end points, sample sizes, and others) are
stored in the registry, data mining can help design better,
more efficient trials that require smaller patient cohorts.
Standardized data formats, such as XML markup language
[12], bring text files into machine-readable form, thus
enhancing automated analysis. Both NCI PDQ and Clini-
calTrials.gov provide clinical trial registry data in the XML
format.
We have developed a data mining approach for rapid
summarization and visualization of information from
clinical trial registries. This method has been applied to
the analysis of cancer vaccine trials and provides conven-
ient means of extraction and presentation of key data
about cancer vaccine trials. The significant progress in can-
cer biology and cancer immunology has not yet been fully
translated into successful clinical vaccine applications
[13]. Though advances in cancer vaccine development
have been reported [e.g. [14,15]], a wide variety of factors
are involved in tumor immune escape, making design and
production of effective therapeutic vaccines difficult.
Increasing knowledge of possible limiting factors include,
among others, dysfunction of the immune system, immu-
nosuppressive effects of tumor microenvironment, pro-
duction of suppressor T cells, defective antigen processing
and presentation, and immunotherapy resistance of
established tumors. To utilize the accumulated data and
knowledge and translate these into improved clinical tri-
als, integration of basic and clinical immunology and
improved data processing capabilities is required. Our
data mining approach provides better understanding of
the cancer vaccine clinical trials landscape, and enables
rapid analysis of the hotspots of cancer vaccine activity, as
well as the identification of neglected cancers. This report
describes the utility of basic data mining techniques of
summarization, tabulation, and visualization applied to
the clinical trials repository data.
Results
Cancer vaccine trials data mining questions
A key characteristic of our application is its versatility;
questions can be formulated and re-formulated rapidly. A
complex, composite question also can be defined directly
from the interface using several mouse clicks. This appli-
cation has been designed to dynamically generate graphs,
summarizing data across relevant clinical trials.
Our application supports formulating basic questions and
queries. A representative, yet not exhaustive list of basic
questions and queries is shown in Table 1. Answers to
questions such as "How has the cancer vaccine field
evolved in the last ten years?" and "How many cancer vac-
cine trials have been conducted; how many of them are
currently open in the United States?" offer a historical
view of the vaccine trials field. Similarly, answers to ques-
tions like "What cancer types are currently researched in
clinical trials?" and "What phase are these trials?" offer an
up-to-date view of the cancer vaccine field. In addition,
this application helps answer more specific questions
such as "How many breast cancer vaccine trials were con-
ducted by Dana-Farber Cancer Institute's Cancer Vaccine
Center and what types of vaccines were used for those tri-
als?"
The versatility of this system enables the analysis of vari-
ous dimensions of the clinical trials landscape, includingImmunome Research 2008, 4:7 http://www.immunome-research.com/content/4/1/7
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clinical trials by timeline, type of cancer, lead institution,
patient population, and/or specific vaccine technology.
Trials over time
Figure 1 summarizes the number of clinical cancer vaccine
trials conducted in the US each year during the last 30
years. The first autologous tumor cell vaccine was used in
a lung cancer trial as early as 1971 at the University of
Medicine and Dentistry in New Jersey. Clinical trials using
vaccine technology gradually re-emerged in the early
1990s, and the field grew rapidly until 2000, with more
than 30 vaccine trials starting in that year. Since then new
cancer vaccine trials have shown a steady increase reach-
ing more than 60 new vaccine trials each year. Most of the
earlier trials were phase I and II. The number of phase III
clinical vaccine trials has increased steadily during the
past three years.
Types of cancers most often targeted by vaccine strategy
Clinical vaccine trials by cancer type and trial phase are
shown in Table 2. The top five cancers targeted by vaccine
therapy in clinical trials are: melanoma, cervical, prostate,
breast, and leukemia. Melanoma has attracted by far the
most attention among cancers; nearly a quarter of all clin-
ical vaccine trials target melanoma. Cervical cancer is sec-
ond, with 10% of total vaccine trials. In addition, each of
prostate, leukemia, breast, lung, lymphoma, and kidney
cancers has been studied in more than twenty clinical vac-
cine trials. Phase III clinical vaccine trials of cervical cancer
vaccines represent the largest group making 47% of the
total number trials.
Institutions and corporations most active in developing 
cancer vaccines
The breakdown of institutions that are major lead spon-
sors of cancer vaccine trials, the total number of trials, and
trial phases, are shown in Figure 2a. The cancer centers
that are included in this list are well known for provision
of comprehensive cancer care and treatments. The results
show that, to date, phase III cancer vaccine trials have
been sponsored almost exclusively by pharmaceutical cor-
porations. The exceptions are two phase III trials spon-
sored by the NCI. The graphs representing various
activities and details can be generated by the data mining
application. Examples of generated graphs are shown in
Figure 2: a) activities by the leading players (institutions
that have sponsored more than ten clinical trials each
within the vaccine field, b) number of vaccine trials with-
out trial phase information, by technology platform for
Dana-Farber Cancer Institute (DFCI), and c) types of can-
cer with trial phases sponsored by DFCI. Similar graphs
depicting the number of cancer vaccine trials can be gen-
erated for the following queries: type of cancer, phase of
clinical trial, sponsor, and vaccine technology. Other que-
ries can be easily formulated.
Table 1: Sample questions that can be answered by this system.
Examples of cancer vaccine trials landscape questions:
1. How many vaccine trials have started each year since 1995?
2. How many of these trials are currently open?
3. Who are the lead sponsors for these trials?
4. What are the main vaccine platforms used by these sponsors in the trials?
5. Do they focus on certain cancer types or on specific vaccine platform?
6. What are the cancer types that have been interrogated using vaccine strategy?
7. What are the cancer types that are currently interrogated?
8. What phase are these trials?
9. Is there any linkage between cancer prevalence and the numbers of vaccine trials for that particular cancer?
10. Are there any cancers neglected within the vaccine field?
Representative questions specific to the cancer vaccine field are shown. Because of the large number of searchable terms and their combinations
Cancer vaccine trials started per year Figure 1
Cancer vaccine trials started per year. The number of 
trials started each year is shown. Bars represent the total 
number of trials started for a particular year. The color code 
on each bar represents the phase of the trials (green: phase 
1; yellow: phase 2; red: phase 3; grey: unspecified).Immunome Research 2008, 4:7 http://www.immunome-research.com/content/4/1/7
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Trials by disease prevalence
In the previous section, we have identified the cancer
types most often targeted by vaccine strategies, represent-
ing actively-supported areas of cancer vaccine trials. We
also wanted to know vaccine trial activities for other can-
cer types. Figure 3 displays the scatter plot of the 5 year
survival rate against the incidence rate for various cancer
types. This figure shows that most of clinical vaccine trials
target cancers with high incidence rates, such as breast,
prostate and lung cancers. In addition, most clinical vac-
cine trials target cancers associated with high rates of 5-
year survival. This figure clearly shows the "neglected can-
cers" within the cancer vaccine landscape, including blad-
der, liver, pancreatic, stomach, esophageal, and all of the
low-incidence cancers.
Technology platforms used by vaccine strategies
The analysis of technology platforms used in the vaccine
trials is shown in Figure 4a. It is not surprising to see that
the majority of the trials use antigens to directly stimulate
host immune response against cancer cells. These antigen
vaccines can be full length proteins or truncated (peptide)
forms. Cellular vaccine trials are second in number to
antigen-based vaccine trials; together they make some
80% of the total. Currently most of the cell vaccines are
made from autologous cells harvested from patients.
Table 2: Vaccine trial counts by cancer types and trial phase.
Cancer Type Phase 1 Phase 2 Phase 3 Phase 4 Unspecified Total
Melanoma 43 107 9 7 166
Cervix 6 23 35 1 5 70
Breast 37 27 1 4 69
Prostate 20 37 4 3 64
Lung 25 28 5 2 60
Ovary 24 11 1 3 39
Non-Hodgkin lymphoma 7 20 7 1 2 37
Colon 11 22 3 36
Kidney 7 23 2 32
Rectum 9 18 3 30
Pancreas 8 17 3 1 29
CML 9 14 1 24
AML 9 10 1 3 23
Myeloma 5 12 2 2 21
Brain 11 8 1 20
Eye 4 14 2 20
Other oral cavity 10 5 15
Pharynx 10 4 1 15
Mouth 10 4 14
All sites 10 3 1 14
Liver 5 7 2 14
CLL 8 5 13
Soft tissue 7 5 1 13
Stomach 8 3 11
Esophagus 6 2 8
Hodgkin lymphoma 2 5 1 8
ALL 3 2 2 7
Bladder 5 1 1 7
Bone 3 2 1 6
Vulva 1 4 5
Testis 3 1 4
Vagina 4 4
Cranial nerves & other nervous system 1 1 1 3
Gallbladder & other billiary 2 1 3
Small intestine 1 1 1 3
Anus 1 1
Corpus 1 1
Other non-epithelial skin 1 0 1
Penis 1 1
Tongue 1 1
Total 189 348 72 2 34 645
The number of vaccine trials per cancer type and trial phase are illustrated. The columns are sorted by total trial number per cancer.Immunome Research 2008, 4:7 http://www.immunome-research.com/content/4/1/7
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Number of trials conducted by each lead sponsor Figure 2
Number of trials conducted by each lead sponsor. (a) The number of cancer vaccine trials conducted by each lead spon-
sor is plotted as a bar graph by the name of the sponsor. Only the sponsors who have conducted more than 10 cancer vaccine 
trials are depicted here. The height of the bar and the number on top of each bar represent the total number of trials for a 
sponsor. The bars are also color coded according to the phase of the trials. Green: phase 1; Yellow: phase 2; Red: phase 3; 
Grey: phase unspecified. (b) A bar graph depicts the vaccine platform profile for Dana-Farber Cancer Institute. The bar heights 
represent the number of the trials conducted using each vaccine platform. (c) A bar graph depicts cancer types targeted in can-
cer vaccine trials at Dana-Farber Cancer Institute. The bar heights represent the number of the trials and the bars are color 
coded using the same color scheme as 3(a).
(a)
(b)
(c)Immunome Research 2008, 4:7 http://www.immunome-research.com/content/4/1/7
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However, allogeneic cell vaccines are becoming more
popular in the last three years (data not shown). We also
observed that individual institutions preferentially pursue
a small number of cancer vaccine strategies. For illustra-
tion, DFCI pursues mainly cellular or viral technology
strategies in developing their vaccine platforms (Figure
4b), while Sloan Kettering Memorial Cancer Center
focuses mainly on antigen-based vaccines (Figure 4c).
Conclusion
A large number of records are available in clinical trial
repositories but the analysis is limited to simple queries.
This data mining application for summarization and vis-
ualization of clinical trials data was developed and
applied to the analysis of cancer vaccine clinical trials
landscape. It enables complex queries of cancer vaccine
trials data through data mining. Data mining revealed
hidden patterns, trends and biases in the data. The appli-
cation enables formulating queries and asking specific
questions. It revealed the cancer vaccine trials develop-
ment over time. The most common cancers targeted by
vaccine therapy in clinical trials are: melanoma, cervical,
prostate, breast, and leukemia. Neglected cancers include
bladder, liver, pancreatic, stomach, esophageal, and all of
the low-incidence cancers. Our approach provides a
bird's-eye view of the cancer vaccine landscape, and ena-
bles rapid analysis of the hotspots of cancer vaccine activ-
ity, as well as the identification of neglected cancers.
Discussion
The landscape of clinical vaccine trials has multiple
dimensions. These include an historical timeline of cancer
vaccine trials, organizations sponsoring vaccine trials,
principal technologies, and types of cancers, all of which
we analyzed in this study. Many of the fields in the XML
files were not included in this study, for example, "mini-
mum age", "maximum age", "inclusion criteria", "exclu-
sion criteria", and others. The selection of fields was
defined by the scope of this study: rapid extraction of clin-
ical trials statistics and identification of major activities in
the field.
For studies that focus on other questions, such as patient
groups, different sets of questions would be asked and dif-
ferent dimensions would be included for selections of rel-
evant fields from the XML files.
Vaccine trials activity relative to cancer prevalence and survival Figure 3
Vaccine trials activity relative to cancer prevalence and survival. Scatter plot of five year survival rate against cancer 
incidence rate for major cancers. Each circle represents an individual cancer type. The incidence rate (cases per 100,000 popu-
lation) on the x-axis is log scaled for visual clarity. The red color of the circles represents the number of trials that have been 
conducted for that cancer type – the higher the number, the darker the circle. Grey circles represent cancer types which have 
not been studied using clinical vaccine trials. Selected cancer types are labeled.Immunome Research 2008, 4:7 http://www.immunome-research.com/content/4/1/7
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Profile of vaccine technologies used in vaccine trials Figure 4
Profile of vaccine technologies used in vaccine trials. (a) Bar graph of total number of cancer vaccine trials conducted 
for each vaccine platform. The bar height and the number on top of the graph represent trial count, though single vaccine trials 
may at times incorporate multiple vaccine platforms; (b) Vaccine platforms for Dana-Farber Cancer Institute vaccine trials; (c) 
Vaccine platforms for Memorial Sloan-Kettering Cancer Center. The color coding is the same as used in Fig 1. When the vac-
cine technology is not known for the trial, it is labeled as "Empty".
(a)
(b)
(c)Immunome Research 2008, 4:7 http://www.immunome-research.com/content/4/1/7
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The decision by the US Food and Drug Administration
(FDA) to publicize information on clinical trials was
made to enable public access to data that address ques-
tions about the safety of certain drugs [5]. In addition,
public access to this data helps counter publication bias,
in which positive results are published more easily and
faster than negative results [5]. Though a significant quan-
tity of data and information that describe cancer vaccine
clinical trials is available, the existing means of converting
these data into knowledge are less advanced.
Our data mining process consisted of data preparation
and the application of summarization [see [11]] and visu-
alization [see [16]] tools upon extracted specific knowl-
edge from cancer vaccine clinical trials data. By accessing
comprehensive clinical trials information using appropri-
ate software tools, several mouse clicks provide access to
knowledge that would otherwise require hiring of special-
ists or consultants. This knowledge is useful for various
professionals, including research directors and planners
in companies, hospital administrators, researchers and
scientists, physicians conducting clinical trials, policy
makers, grant officers at funding bodies, and government
regulators. By combining public databases of clinical tri-
als, data formatting by XML, and computational analysis
and visualization, we have shown that specific knowledge
can be extracted, summarized, and presented to the user.
We have implemented a highly flexible system to visualize
and mine clinical trial information in the cancer vaccine
field. We obtained all data about cancer vaccine trials
from ClinicalTrials.gov database. In accordance with the
1997 FDA Modernization Act [17], information from clin-
ical trials on serious or life-threatening diseases must be
registered at ClinicalTrials.gov within 21 days of the trial
starting date. The ClinicalTrials.gov has become the
world's largest clinical trial database and it contains infor-
mation from clinical trials performed world-wide.
Although some cancer vaccine trials may not necessarily
be included, ClinicalTrials.gov repository is comprehen-
sive and representative of the world-wide landscape of
clinical trials in the cancer vaccine field. Some fields of
interest in this study were not included in the original
XML files; for example, fields related to specific vaccine
technology. We inspected the records, identified vaccine
technology, and manually annotated this field using
external data sources. In addition, clinical trials records in
the back-end database were enriched with fields contain-
ing cancer statistics data. Manual annotation of these data
has limitations, principally because subsequent studies
also need manual annotation. This shortcoming can be
addressed either by automation of annotation, or by
inclusion of these fields in the clinical trials records. We
envision that the power of this system can only increase
with the improvement of the content of public databases.
Methods
Data
Of 16,000 cancer trials in ClinicalTrials.gov, some 900 are
cancer vaccine or cancer immunotherapy trials. The infor-
mation provided in the trial descriptions includes "sum-
mary of purpose", "trial sponsor", "phase of the trial",
"recruiting status", and "location", and other, more spe-
cific information. Clinical trials related to cancer vaccines
are defined by keywords "cancer" and "vaccine" present in
the title or abstract of the trial record. Prior to January
2008, some 642 trials fit this definition. Input primary
data consisted of downloaded XML files containing infor-
mation on cancer vaccine trials.
Additional information on cancer types was retrieved
from the Surveillance Epidemiology and End Results
(SEER) Cancer Statistics Review (CSR) provided by the
National Cancer Institute (NCI). Incidence and survival
rates associated with various cancer types were obtained
from the SEER/CSR report 2003 [18].
System description
Our data mining system consists of a back-end XML data-
base, a front-end visualization interface, and the analysis
component. The analysis workflow is shown in Figure 5.
First, XML files for relevant cancer vaccine trials were
downloaded from the ClinicalTrials.gov website and inci-
Overview of the system and workflow Figure 5
Overview of the system and workflow. A flowchart of 
the work flow to establish the system is shown here. Data 
relevant to each cancer vaccine trial and cancer prevalence 
data were obtained from public sources and were then fur-
ther annotated to form an XML database. Desired data were 
then retrieved and reformatted before loading into Spotfire 
DXP for visualization. Various graphs were generated with 
each iterative cycle of querying and re-querying until a final 
collection of informative graphs was generated.
Data preparation
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dence and survival facts were downloaded from the
National Cancer Institute (NCI) website. We have defined
a series of questions to address using this system. Fields of
interest contain information, such as 'Cancer Type', 'Phase
of the Trial', and 'Recruiting Status'; these fields were
extracted from the primary XML files. Additional fields of
interest, such as 'Technology Platform', 'Adjuvant Usage',
and 'Therapy type', that provide information in form suit-
able for database querying, were added manually and
associated to each clinical trial record in our back-end
database. These data were not available as separate fields
in the ClinicalTrials.gov records, but could be derived
from the descriptions and mapped. Clinical trial records
contain additional fields such as 'Minimum Age', 'Maxi-
mum Age', 'Inclusion Criteria', 'Exclusion Criteria', among
others. That information was outside the scope of this
study and was not included in the back-end database of
our system. Nevertheless, these fields can easily be
included in the data mining system if needed. The tech-
nology platform information is not available as a separate
field in ClinicalTrials.gov but can be extracted from the
content of other fields and interpreted using data from
NCI Drug Dictionary [19]. The list of applicable technol-
ogies is shown in Table 3. Cancer statistics data are not
available at all in the ClinicalTrials.gov and they were cre-
ated from external data [18] [see Additional file 1]. The
clinical trial data was merged with cancer statistical facts
using "Cancer Type" as the link. Spotfire has the capability
of importing additional data from an external file or data-
base and we used this capability. Several graphical views
were generated to answer specific questions.
Spotfire DXP Platform Description
We have chosen Spotfire-DXP (version 2.0, spot-
fire.tibco.com) software to construct the environment for
our data mining application. Spotfire-DXP is proprietary
software which can be licensed through TIBCO Software
Inc. http://www.tibco.com. The Spotfire-DXP is a
dynamic tool suitable for summarization and visualiza-
tion of tabular data. Although other similar tools, such as
SAS, Insightful, and others offer more sophisticated statis-
tical power, they are less suitable for summarization, vis-
ualization, and tabulation tasks. Spotfire is easy to learn
and use because of graphical user interface that allows
graphing and tabulation by using drag-and-drop actions.
The software environment consists of four main areas,
'Menu Bar', 'Main Graphing Area', 'Query Filter Panel',
and 'Details on Demand'. The top 'Menu Bar' consists of
file and data manipulation tools, in addition to icons for
generating new graphs. The 'Main Graphing Area' is screen
space where user displays results in either graphs or tables.
The right 'Query Filter Panel' is automatically populated
with column heads when the data table is brought in. The
'Details on Demand' window will only show up when a
user wants to investigate a subset of records in more
details.
The interface with representative examples is illustrated in
Figure 6. When the program is started with a selected data
table, the top 'Menu Bar' and the 'Query Filter Panel'
appear, along with the default cover page, and a scatter
plot is automatically generated in the 'Main Graphing
Area'. To change the axis of the graph, the user can simply
drag the appropriate field from the filter panel onto the x
or y axis. To change the type of graph plotted, the user can
click on the "x" symbol at the top right corner of the
"Main Graphing Area" to close the default scatter plot and
click on another graph icon from the top "Menu Bar" to
generate another graph. Axes can then be changed as
described previously. Tables can also be generated using a
similar drag-and-drop action. The properties of a particu-
Table 3: Major cancer vaccine technologies.
Vaccine antigen status Vaccine technology
Defined antigen Dendritic cell (peptide)
Dendritic cell (protein)
Dendritic cell (specific RNA)
Dendritic cell (virus)
Viral vector (antigen)
Viral vector (other)
Naked DNA
Protein
Peptides
Anti-idiotype
Antigen-specific adjuvant
Other
Undefined antigen Dendritic cells (tumor cell pulsed)
Dendritic cells (lysate pulsed)
Dendritic cells (allo-lysate pulsed)
Allogeneic Dendritic cells (lysate pulsed)
Dendritic cells (antigen)
Dendritic cells (non-specific DNA)
Dendritic cells (non-specific RNA)
Dendritic cells (idiotype)
Oncolytic virus
Autologous (tumor lysate)
Allogeneic (tumor lysate)
Autologous (tumor cell)
Allogeneic (tumor cell)
Autologous (T cell)
Autologous (lymphocytes)
Autologous (PBMC)
Immunomodulators
Immune activators
Other non-cancer vaccines
Other
More details about technological platforms for cancer vaccines can be 
found in [20].Immunome Research 2008, 4:7 http://www.immunome-research.com/content/4/1/7
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lar graph can be changed through the property window by
adjusting relevant parameters. Parameters that users can
select include color, shape, size, and other graphical prop-
erties for displaying high dimension data. Once the graph
is generated, the user can plot more detailed graphs by
selecting a subset of data within 'Query Filter Panel'. The
graph will change dynamically upon data filtering and the
corresponding records will be displayed in the 'Details on
Demand' window. The user can generate several graphs
on a single page, as shown in Figure 6. These graphs are
linked; records selected in one graph will also be high-
lighted in all other graphs. Formulated queries are stored
as "pages" shown in the tabs under the toolbar ('Cover
Page', 'Data Table', 'Lead Sponsors – Players', and others).
The user can plot new graphs on a separate page by click-
ing on the 'New Page' icon on the top 'Menu Bar' and gen-
erate graphs as previously described.
Data mining
Tabular data are constructed from the backend database.
Our application uses standard Spotfire-DXP toolbox for
extraction and manipulation of data. Fields that we used
in this study included 'Cancer Type', 'Incidence Rate', '5-
Year Survival (%)', 'Trial ID', 'Brief Summary', 'Lead Spon-
sor', 'Collaborator', 'Phase', 'Trial Status', 'Vaccine Plat-
form', and 'Trial Start' data.
To illustrate the data mining process, we have used an
example in which we answered Question 1 (Table 1) by
generating a bar graph shown in Figure 1. The process
started by selection of the 'Bar Graph' on the 'Menu Bar'.
This generated the default bar graph in the 'Main Graph-
ing Area'. Then, we selected the 'Start Date' field from the
'Query Filter Panel' and dragged it to the x-axis. Similarly,
we dragged the 'TrialID' from the 'Query Filter Panel' to
Data mining framework Figure 6
Data mining framework. A screenshot of the interface to our data mining system. The interface has four major sections: 
menu bar (top), query filter panel (right), database details on demand (bottom), and the main graphing area (central).Publish with BioMed Central    and   every 
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the y-axis. We clicked on the y-axis to apply the 'Unique-
Count' function to the y-axis. Once this was done, we
changed the coloring scheme by clicking the 'Property'
icon in the 'Menu Bar' and specified the colors for differ-
ent phases (green for phase 1, yellow for phase 2 and red
for phase 3.). These actions produced the graph on the
'Trials Started per Year' page. Similarly, we constructed
other pages that query specific information about lead
sponsors, diseases, vaccine technology platform, and geo-
graphic locations, as shown in Figure 6. The data sets and
application programs are available upon request from the
authors.
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